Skip to main content

Young Teresa L.'s Form 4 filing

Seres Therapeutics, Inc. (MCRB) · filed Feb 19, 2025

Accession no.
0000950170-25-023584
Filed
Feb 19, 2025
Trade date
Feb 15-18, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.70K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Young Teresa L.CIK 0001814656Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2025Common StockMOption exerciseAcquired+2,657–F1–93,061Direct
Feb 15, 2025Common StockMOption exerciseAcquired+7,813–F1–100,874Direct
Feb 18, 2025Common StockSSaleDisposed−3,338$0.81F3−$2,703.7897,536Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2025Common StockMOption exerciseDisposed−2,657$0.00$021,250Direct
Feb 15, 2025Common StockMOption exerciseDisposed−7,813$0.00$023,437Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Referenced by the price of 2 transactions in Table I.

F3

The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.832001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

EVP, Chief Commercial & Strategy Officer

Read the full filing on SEC EDGAR (opens in a new tab)